Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cash from Investing Activities (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Cash from Investing Activities data on record, last reported at $49.3 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 182.71% year-over-year to $49.3 million; the TTM value through Dec 2025 reached -$42.1 million, up 78.86%, while the annual FY2025 figure was -$42.1 million, 78.86% up from the prior year.
  • Cash from Investing Activities reached $49.3 million in Q4 2025 per TARS's latest filing, up from -$4.7 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $64.1 million in Q2 2023 and bottomed at -$102.2 million in Q1 2024.
  • Average Cash from Investing Activities over 5 years is -$12.3 million, with a median of -$168000.0 recorded in 2021.
  • Peak YoY movement for Cash from Investing Activities: plummeted 47112.4% in 2022, then soared 52634.43% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$274000.0 in 2021, then crashed by 31731.75% to -$87.2 million in 2022, then skyrocketed by 120.47% to $17.8 million in 2023, then plummeted by 433.75% to -$59.6 million in 2024, then skyrocketed by 182.71% to $49.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $49.3 million in Q4 2025, -$4.7 million in Q3 2025, and -$51.7 million in Q2 2025.